The Motley Fool Previous Page

1 Risk Threatening Eli Lilly

Brian Orelli
December 12, 2012

Today's news that Eli Lilly (NYSE: LLY  ) won't submit Alzheimer's drug candidate solanezumab for FDA approval without running an additional clinical trial sent shares down 3%. This came after discussions with the FDA, which presumably wanted to see an additional study confirm Eli Lilly's assertion that the drug helps those with mild cases of the┬ádisease.

If Eli Lilly gets the study up and running in mid-2013, investors would likely be looking at 2015 before getting results.Considering the terrible track record of this therapeutic class, Johnson & Johnson (NYSE: JNJ  ) , Pfizer (NYSE: